Abstract: A method is disclosed for stabilizing a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to the aqueous liquid at least one compound selected from the group consisting of a nonionic surfactant, a water-soluble, nonionic, organic binder, hydrogenated lecithin, and mannitol.

Abstract: A method is disclosed for stabilizing a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to the aqueous liquid at least one compound selected from the group consisting of a nonionic surfactant, a water-soluble, nonionic, organic binder, hydrogenated lecithin, and mannitol.

Abstract: A method is disclosed for stabilizing a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to the aqueous liquid at least one compound selected from the group consisting of a nonionic surfactant, a water-soluble, nonionic, organic binder, hydrogenated lecithin, and mannitol.

Abstract: The present invention provides a process for purifying Tamm-Horsfall glycoprotein (THG) and uromodulin, which permits THG and uromodulin to be purified with enhanced efficiency by the simplified procedure, as well as a method for making the discrimination between both of them.

Abstract: The present invention provides novel metastasis suppressory agents with a lowered degree of toxicity, comprising ursolic acid or its salt as an active ingredient, which can be administered to patients per os or through injection, thus enabling the patients to receive post-operative ambulatory treatment.

Abstract: The present invention, using a readily available sulfated chitin as an adsorbent, can permit platelet factor-4 to be recovered through specific adsorption from a solution containing the same factor, in by far increased yields as compared with the conventional process utilizing a heparin-immobilized affinity column, and provides the process for isolating, through purification platelet factor-4 which is suited for a commercial-scale, mass production process, wherein there can be offered the advantages of utilization of more readily available sulfated chitin, simplified procedure and improved production yields for the objective substance.

Abstract: Disclosed is an electrode for electrical discharge used for diesinking, comprising an electrode member produced by subjecting a base and binder of gypsum hemihydrate powder and a filler of conductive metal powder to modeling and/or molding and setting into a desired form of electrode, and followed by plating the electrode member with a conductive metal; and a process for manufacturing the same, wherein a gypsum hemihydrate powder, a gypsum dihydrate powder in an amount of 1% by weight of the gypsum hemihydrate powder and a conductive metal powder are kneaded in vacuo, and water is added thereto to continue further kneading in vacuo, followed by casting into a mold having a predetermined shape transferred thereon to carry out hydration, molding and setting to provide an electrode member; after the electrode member is dried, it is plated with a conductive metal to enhance mutual continuity in the conductivity of the former conductive metal powder and also to form a thin metal layer on the surface of the electro

Abstract: The thermal degradation of urokinase in an aqueous solution is suppressed by heating an aqueous solution containing urokinase in the presence of citric acid or a water-soluble salt thereof such as sodium, potassium or lithium citrate at about 60.degree. C. for about 10 hours.